Log In
Thursday 18th July 2019

AstraZeneca sales fall

25th October 2012

Latest figures from AstraZeneca show that company’s sales dropped by a bigger-than-expected 19% in the third quarter.

Analysts say that the figures underscore the challenges facing the company’s new chief executive, Pascal Soriot, who joined from Roche on October 1. AstraZeneca is faced with patent expires on once best-selling medicines and has a thin pipeline of new drugs, meaning Soriot will need to re-focus operations and step up the hunt for acquisitions. Soriot has told reporters that buying in products would be an important way of rebuilding the pipeline.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2019